We found increased calreticulin staining on the cell surface of MNNG/HOS tumor cells undergoing doxorubicin or combination treatment compared to PBS‐treated or CD47 mAb‐treated tumor cells (Fig. 1D,E, P = 0.0001). The gene discussed is CALR; the disease is neoplasm.